Table 9.
Meta-analytic studies of randomized controlled trials of BCMA-targeted CAR T-cells for RRMM.
| Reference | No. of Trials | Total No. of Patients | Efficacy | Toxicity | ||||
|---|---|---|---|---|---|---|---|---|
| Pooled ORR | Pooled CRR | Pooled MRD Negativity | Median PFS (Months) | CRS ≥ Grade 3 | Neurotoxicity (ICANS/CRES) | |||
| [217] | 27 | 497 | 89% | 13% | 81% | NR | 76% | 8% |
| [218] | 27 | 630 | 80.5% | 71.9% | 28 a/68 b | 12.2 | 14.1% | 20.4 a/1.8 b |
| [219] | 30 | 950 | 78.3% | NR | NR | NR | 6.4 | 3.5% |
| [220] | 23 | 350 | 77% | 37% | 78% | 8 | 14% | 13% |
| [221] | 22 | 681 | 85.2 | 47.0% | 97.8% | 14.0 | 6.6% | 2.2% |
| [222] | 10 | 353 | NR | 55% | NR | NR | 8.0% | NR |
| [223] | 15 | 285 | 82% | 38% | 77% | 10 | 15 | 18 |
| [224] | 20 | 447 | 84% | 36% | 83% | 10 | 15% | 17% |
| [225] | 15 | 285 | 82% | 36% | 77% | 10 | 15% | 18% |
| [226] | 21 | 761 | 87% | 44% | 78% | 8.77 | 11% | 10% |
CRES = CAR T-cell-related encephalopathy syndrome; CRR = complete response rate; CRS = cytokine release syndrome; ICANS = immune effector cell-associated neurotoxicity syndrome; MRD = minimal residual disease; ORR = overall response rate; PFS = progression-free survival. a Lymphodepletion with cyclophosphamide/fludarabine; b lymphodepletion with cyclophosphamide